HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Lu AF35700

dopamine and serotonin receptor antagonist

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - Lu AF35700: 2

Related Diseases

1.	Treatment-Resistant Schizophrenia 10/01/2022 - "Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension." 10/01/2022 - "We hypothesized that the synergistic activity of Lu AF35700 at dopamine D1 and D2 receptors might provide superior antipsychotic effects versus first-line antipsychotic therapy in patients with treatment resistant schizophrenia (TRS), with a benign tolerability profile. "
2.	Schizophrenia (Dementia Praecox) 08/15/2023 - "Here, we examined the ability of Lu AF35700 (preferential D1-R>D2-R antagonist), to reverse the alterations in thalamo-cortical activity induced by phencyclidine (PCP), used as a pharmacological model of schizophrenia. "
3.	Headache (Headaches) 10/01/2022 - "The most common adverse events with Lu AF35700 were increased weight and headache. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Phencyclidine (Angel Dust)
3.	Dopamine (Intropin)

Related Therapies and Procedures

1.	Therapeutics